Showing results (1531-1540 of 2,107) with videos related to

Sort By:
Pageof 211
CNS Drugs|April 15, 2025
Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5-HT2AR Antagonist (VVZ-2471) in a Randomized, Double-Blind, First-in-Human StudySungyeun Bae, HyunJoon Lee, Inkyung Song, et al.
CNS Drugs|March 20, 2025
Efficacy of Once-Nightly Sodium Oxybate in Patients with Narcolepsy: Post Hoc Analyses of Sensitivity, Effect Size, and Numbers Needed to Treat from the Phase 3 REST-ON TrialThomas Roth, Michael J Thorpy, Clete A Kushida, et al.
CNS Drugs|March 15, 2025
Update on Neuroprotection after Traumatic Brain InjuryAaron M Cook, Morgan Michas, Blake Robbins
CNS Drugs|June 27, 2024
Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy DevelopmentJeffrey L Cummings, Amanda M Leisgang Osse, Jefferson W Kinney, et al.
CNS Drugs|June 5, 2024
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer's DiseaseMichael H Rosenbloom, Tricia O'Donohue, Domi Zhou-Clark, et al.
CNS Drugs|May 31, 2024
Intervening in the Premonitory Phase to Prevent Migraine: Prospects for PharmacotherapyNazia Karsan, Peter J Goadsby
CNS Drugs|June 3, 2024
Targeting Biometals in Alzheimer's Disease with Metal Chelating Agents Including Coumarin DerivativesAdrián Gucký, Slávka Hamuľaková
CNS Drugs|July 20, 2024
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and ChallengesAnton Gomez-Escolar, Daniel Folch-Sanchez, Joanna Stefaniuk, et al.
CNS Drugs|June 23, 2024
The Use of Ketamine for the Treatment of Anhedonia in DepressionLiliana Patarroyo-Rodriguez, Stefanie Cavalcanti, Jennifer L Vande Voort, et al.
CNS Drugs|December 13, 2025
The Effect of Psychotropic Medications on Glaucoma Risk and Intraocular Pressure: A Bayesian Meta-AnalysisTommaso B Jannini, Ludovico Alisi, Francesca Giovannetti, et al.
Pageof 211